PIRS Stock Overview
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Pieris Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.08 |
52 Week High | US$80.80 |
52 Week Low | US$10.60 |
Beta | 0.50 |
1 Month Change | -19.38% |
3 Month Change | -20.86% |
1 Year Change | -83.88% |
3 Year Change | -92.82% |
5 Year Change | -95.82% |
Change since IPO | -94.67% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18Recent updates
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Shareholder Returns
PIRS | US Biotechs | US Market | |
---|---|---|---|
7D | -5.5% | 4.8% | 0.7% |
1Y | -83.9% | 2.8% | 23.9% |
Return vs Industry: PIRS underperformed the US Biotechs industry which returned 2.7% over the past year.
Return vs Market: PIRS underperformed the US Market which returned 23.9% over the past year.
Price Volatility
PIRS volatility | |
---|---|
PIRS Average Weekly Movement | 10.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PIRS's share price has been volatile over the past 3 months.
Volatility Over Time: PIRS's weekly volatility has decreased from 16% to 10% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 48 | Steve Yoder | www.pieris.com |
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Pieris Pharmaceuticals, Inc. Fundamentals Summary
PIRS fundamental statistics | |
---|---|
Market cap | US$13.70m |
Earnings (TTM) | -US$24.54m |
Revenue (TTM) | US$42.81m |
0.3x
P/S Ratio-0.6x
P/E RatioIs PIRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PIRS income statement (TTM) | |
---|---|
Revenue | US$42.81m |
Cost of Revenue | US$41.80m |
Gross Profit | US$1.01m |
Other Expenses | US$25.55m |
Earnings | -US$24.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -19.85 |
Gross Margin | 2.36% |
Net Profit Margin | -57.33% |
Debt/Equity Ratio | 0% |
How did PIRS perform over the long term?
See historical performance and comparison